Atossa Therapeutics (NASDAQ:ATOS) Earns “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Atossa Therapeutics (NASDAQ:ATOSFree Report) in a research note released on Thursday, Benzinga reports.

A number of other equities research analysts also recently weighed in on the company. StockNews.com raised Atossa Therapeutics from a sell rating to a hold rating in a report on Tuesday, May 14th. HC Wainwright boosted their price objective on shares of Atossa Therapeutics from $4.00 to $6.00 and gave the company a buy rating in a report on Monday, May 13th. Finally, Ascendiant Capital Markets increased their target price on shares of Atossa Therapeutics from $6.00 to $6.25 and gave the stock a buy rating in a research report on Thursday, June 6th.

Get Our Latest Stock Analysis on ATOS

Atossa Therapeutics Price Performance

NASDAQ:ATOS opened at $1.13 on Thursday. The firm’s fifty day moving average price is $1.43 and its two-hundred day moving average price is $1.22. The company has a market cap of $142.11 million, a P/E ratio of -4.71 and a beta of 1.19. Atossa Therapeutics has a one year low of $0.62 and a one year high of $2.31.

Atossa Therapeutics (NASDAQ:ATOSGet Free Report) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.02. As a group, equities research analysts expect that Atossa Therapeutics will post -0.23 earnings per share for the current year.

Insider Activity at Atossa Therapeutics

In other news, Director Jonathan Finn acquired 25,000 shares of Atossa Therapeutics stock in a transaction on Wednesday, April 10th. The shares were purchased at an average cost of $1.77 per share, for a total transaction of $44,250.00. Following the completion of the purchase, the director now directly owns 25,000 shares of the company’s stock, valued at approximately $44,250. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 7.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Atossa Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. PFG Investments LLC acquired a new stake in Atossa Therapeutics in the first quarter valued at about $43,000. Cetera Advisors LLC acquired a new position in Atossa Therapeutics during the 1st quarter worth approximately $72,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in Atossa Therapeutics in the 3rd quarter valued at approximately $98,000. Virtu Financial LLC acquired a new stake in Atossa Therapeutics in the first quarter valued at approximately $151,000. Finally, Vanguard Group Inc. grew its stake in shares of Atossa Therapeutics by 1.4% during the first quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock worth $10,357,000 after buying an additional 78,269 shares during the last quarter. Institutional investors own 12.74% of the company’s stock.

Atossa Therapeutics Company Profile

(Get Free Report)

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

Further Reading

Receive News & Ratings for Atossa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.